An element to be managed for mammals or for human life
Patent Information
- Application Number
- LAP63
- Authority / Receiving Office
- LA · LA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2005-09-19
- Filing Date
- 2006-09-15
- Publication Date
- 2025-09-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current chemotherapy treatments for cancer face significant resistance mechanisms in tumor cells, leading to low efficacy and severe side effects due to non-specificity, with existing antineoplastic drugs often failing to effectively target and kill cancer cells, especially at advanced stages.
A composition comprising empty pegylated liposomes and specific monoclonal antibodies or structural proteins, such as talin, that interact with cancer cells to create large openings in the cell membrane, disrupting osmotic balance and causing the release of intracellular content into the extracellular medium, effectively inducing cell lysis without the use of chemical therapeutic agents.
This approach offers high specificity and selectivity, minimizing side effects and overcoming resistance mechanisms, resulting in a treatment with zero toxicity profile and enhanced lethal power against cancer cells and pathogenic microorganisms, while maintaining prolonged activity and gradual administration.
Abstract
Description
[0001] The Description
[0002] A COMPOSITION TO BE ADMINISTERED TO A MAMMAL OR A HUMAN BEING
[0003] A COMPOSITION TO BE ADMINISTERED TO A MAMMAL
[0004] OA A HUMAN BEING
[0005] [1] A COMPOSITION TO BE ADMINISTERED TO A MAMMAL OA
[0006] A HUMAN BEING
[0007] [2] FIELD OF THE INVENTION
[0008] [3] The composition to be administered to a mammal or a human being has its field of application as a therapeutic agent, as an effector capable of interacting with an altered cell or a pathogenic microorganism in order to disturb the osmotic balance and provide for the elimination of the intracellular contents to the extracellular environment.
[0009] [4] It is intended as an antineoplastic agent in the treatment of cancer, and is also applicable to the treatment of diseases caused by cells, bacteria, viruses, unicellular or multicellular organisms or others, in which their outermost envelope is composed of a lipid membrane, such as the cell membrane of eukaryotic cells, or the one that surrounds the AIDS virus (HIV).
[0010] [5] RELATED PRIOR TECHNIQUE
[0011] [6] In the cellular realm, apoptosis refers to the active process, with morphological changes, in which cells are destined to die within a fixed time; the term necrosis refers to the violent and catastrophic processes that frequently appear as a result of exposure to toxins or traumatic damage caused to the cell membrane with acute loss of regulation and cellular function, which entails an excessive osmotic process and ends with the death or lysis of the cell membrane, releasing the intracellular contents into the extracellular environment.
[0012] [7] Tumors arise from a succession of cumulative mutations that occur in a cell and are transmitted through successive cell divisions. The mutation rate depends on the genetic instability of each tumor, and when a tumor grows large enough to be clinically detectable, the number of mutations is so high that the cells spontaneously develop resistance to some chemotherapeutic agents. At the time of tumor diagnosis, the number of resistant cells is proportional to the tumor's size and its intrinsic mutation rate.
[0013] [8] Tumor cell resistance to chemotherapy is determined by the kinetics of their growth and by the occurrence of spontaneous mutations. Although proliferative tumor cells are affected by most chemotherapeutic agents, The effect on tumor cells with low activity is practically nil and since most tumors are diagnosed at an advanced stage of their development, with a low growth fraction, they are not very sensitive to the action of chemotherapeutic agents.
[0014] [9] Chemotherapeutic treatments aim to damage cancer cells, particularly their DNA, and induce apoptosis. To achieve this, it is necessary to ensure that the largest possible amount of the active drug reaches its molecular target inside the damaged cell. Any external or internal circumstance that interferes with or hinders this objective can cause cellular resistance.
[0015]
[0010] Virtually all chemotherapy treatments based on cytostatic agents that have been affected in vitro by some resistance mechanism penetrate the cell by passive diffusion. Therefore, the higher the extracellular concentration of the drug, the greater the amount that penetrates the cell and the greater its efficacy.
[0016]
[0011] Intracellular resistance mechanisms represent the greatest influence on the failure of chemotherapy treatments. Thus, the decrease in drug concentration at its molecular target is due, among other causes, to its expulsion through the cell membrane by means of transport proteins, the encapsulation of chemotherapeutic drug molecules in cytoplasmic vesicles and variations in transport between the nucleus and the cytoplasm, as well as the alteration of the drug's intracellular metabolism through its inactivation by oxidation and / or conjugation with glutathione (GSH), and its subsequent expulsion from the cell by means of chemical pumps.
[0017]
[0012] Most cytotoxic drugs used as antineoplastic agents cause alterations in DNA structure that should induce cell apoptosis, although the increased capacity for DNA repair cancels the effect of the drugs. The p53 gene should initiate cell apoptosis, but it has been found that in many cancer cells this gene is mutated, or even missing, which means that even if the altered cells have suffered damage from the effect of cytotoxic drugs, apoptosis does not occur and the cells continue to divide.
[0018]
[0013] Cytostatic agents are the most widely used antineoplastic agents in chemotherapy today. They exert their effect by causing breaks and / or alterations in the DNA of cancer cells, inducing apoptosis and cell death, with the aforementioned exceptions. Their relatively low specificity leads to side effects, as in addition to attacking cancer cells, they also destroy gastric mucosal cells and attack cells of the immune system, causing severe neutropenia in patients and leaving them defenseless against any opportunistic infection or disease that can cause death.
[0014] New drugs, based on monoclonal antibodies and liposomes, have been developed to minimize side effects in patients. Monoclonal antibodies in antineoplastic drugs can only bind to a specific antigen previously identified on the cancer cells that need to be eliminated; therefore, the active ingredient attached to the antibody will only affect the cancer cells that possess that antigen. With these drugs, the aforementioned side effects practically disappear.
[0019]
[0015] Even more optimal is the use of pegylated liposomes with tumor-specific monoclonal antibodies, to which the active ingredient of the antineoplastic drug is anchored. Liposomes are vesicles formed by phospholipids with a composition very similar to that of the cell membrane, which allows the liposome to fuse with the cell membrane and ensures the penetration of the active ingredient contained within the liposome into the cell. With the use of drugs administered via liposomes, the antineoplastic activity in the blood is maintained for a longer period, its administration is gradual, and side effects are even fewer in the patients treated.However, despite improving quality of life and survival rates, this chemotherapy solution is expensive and its results are modest against the resistance mechanisms of cancer cells. Therefore, the public health system rarely uses it, even though current chemotherapy is effective in some cases, such as childhood leukemia. Most patients with metastases and solid tumors die. Thus, it is necessary to find a new type of chemotherapy that overcomes the resistance mechanisms to current antineoplastic drugs, which would mean salvation for millions of people worldwide.
[0020]
[0016] OBJECT OF THE INVENTION
[0021]
[0017] An object of the invention is to propose a composition to be administered to a mammal or a human being in order to combat a disease caused by altered cells, bacteria, viruses, or other organisms whose outer envelope is a lipid membrane.
[0022]
[0018] Another object of the invention is a cancer treatment with zero toxicity profile and a mechanism of action essentially different from that used in conventional treatments.
[0023]
[0019] SUMMARY OF THE INVENTION
[0024]
[0020] Liposomes have also been used as structures without a classic active ingredient in multiple activities (antihypertensive, anti-inflammatory, etc.), although their use as empty liposomes lacking an active ingredient against altered cells, especially cancer cells, is unknown. Prior to this invention, the combined use of pegylated liposomes and monoclonal antibodies, in the absence of antineoplastic agents, for use in the treatment of cancers and diseases had never been considered. diseases caused by viruses, bacteria or others, and specifically to ensure the release of the intracellular contents of an altered cell or microorganism into the extracellular environment, lysis and its death.
[0025]
[0021] In general, the invention involves compositions and methods for treating altered cells. More particularly, the invention involves compositions lacking chemical-therapeutic content but consisting of liposomes, monoclonal antibodies, and structural proteins. Administration of these compositions to a human or animal with cellular damage results in cell rupture, the release of the intracellular contents of the damaged cells into the extracellular environment, and subsequent lysis. This circumvents cellular resistance mechanisms.
[0026]
[0022] The present invention further provides a method for administering the composition to a human being or an animal suffering from a cellular disease, such as cancer, including, but not limited to, carcinomas, leukemias, myelomas, neuroblastomas, sarcomas, of the lung, brain, ovary, colon, or breast. This method generally comprises administering to the individual a quantity of the composition that represents an effective amount capable of initiating the lytic process in the plasma membrane of the altered cells and, where applicable, of the pathogenic microorganisms. The effective quantities are determined after medical diagnosis.
[0027]
[0023] Examples of compositions that induce cell opening include disease-specific monoclonal antibodies anchored to liposomes or vesicles that include structural proteins arranged on their outer surfaces delimiting openings of considerable size that, in the interaction of the liposome with a damaged cell, are kept open to induce plasma spillage into the extracellular medium, lysis, and death of the damaged cell.
[0028]
[0024] Monoclonal antibodies, according to the invention, can be replaced by alcohols or glycoproteins also specific to the cell or microorganism to be destroyed.
[0029]
[0025] Accordingly, a composition is provided to be administered to a mammal or a human being in order to combat a disease caused by altered cells, bacteria, viruses, or other microorganisms whose outer envelope is a lipid membrane.
[0030]
[0026] A treatment for the disease with zero toxicity profile and a mechanism of action essentially different from that used in conventional treatments against damaged cells is also provided. The proposed treatment's mechanism of action, which lacks chemical therapeutic agents, bypasses the resistance mechanisms exhibited by target cells, such as cancer cells, unlike conventional antineoplastic agents.
[0031]
[0027] The composition to be administered to a mammal or a human being is prepared, in a known manner, using liposomes, structural proteins and elements of specific anchoring.
[0032]
[0028] Administration of the composition to a disease-affected mammal or human initiates the lytic process in the target cells or microorganisms to be destroyed and the elimination of the intracellular contents to the extracellular medium through the large openings, initially originated in the liposome's lipid membrane by the protein and substantially maintained as discharge mouths after the interaction of the liposome's lipid membrane with the plasma membrane of the target cells or microorganisms to which its action is directed.
[0033]
[0029] More specifically, the present invention provides a cancer treatment composition comprising a preferably unilamellar liposome, in whose structure a large opening has been defined with the integration of a structural protein, and whose membrane incorporates antibodies specific to the damaged cell to be treated so that the docking of the vesicles to the corresponding tumor cell receptors allows the fusion of the vesicle and specific cell membranes. Once the liposomes dock to the target cells and their membranes fuse, the openings in the liposomes become release ports that connect the cytoplasm to the extracellular environment; this modifies the osmotic pressure and initiates the lytic process leading to cell death.
[0034]
[0030] According to the invention, a preferred composition for administration to a mammal or a human being in order to destroy an altered and damaged cell or a pathogenic microorganism, includes an empty unilamellar liposome, the structure of which has an opening delimited by a structural protein element and whose membrane incorporates specific anchoring elements, for example, monoclonal antibodies chosen, where appropriate, according to the cell to be destroyed, so that in its administration to the patient the composition becomes an effective effector agent capable of interacting with the membrane of the target cell or with the membrane of the microorganism and, in its fusion with it, substantially maintain the opening in the liposome in order to disturb the cellular osmotic balance, and the opening being further used as a mouth for pouring the intracellular contents into the extracellular medium.
[0035]
[0031] Substantially, the empty unilamellar liposome present in the composition is procured from a specific lipid composition adapted to the target cell or microorganism to be destroyed.
[0036]
[0032] According to the invention, talin is preferred as a structural protein element modifying the liposome in the use of the intended composition.
[0037]
[0033] Treatments based on the use of the recommended composition make use, like conventional treatments, of monoclonal antibodies or other specific anchoring elements and liposomes, although without the drawbacks that The active ingredients incorporated in these liposomes are harmless to the body, as they consist only of phospholipids and proteins. In a neoplastic disease, the lethal effect of the composition on tumor cells is due to the opening and maintenance of a release port in the cell membrane, which empties the cell's contents after the interaction of the liposome with a structural protein, preferably talin, which creates a large opening in the liposome. The size of these openings can be pre-selected and they are permanent in the liposome. Consequently, the fusion of liposomes with the membranes of damaged cells creates and maintains an opening of substantially the same size in the cell membrane. The attachment of multiple liposomes to the tumor cell membrane also creates corresponding openings that will cause immediate cell lysis and death.
[0038]
[0034] As stated above, the main advantages of this composition for administration to a mammal or human being in the treatment of altered cells become evident compared to currently used antineoplastic treatments. These include: high specificity, which aims to reduce or eliminate treatment side effects; the complete lack of resistance offered by the membranes of altered cells or microorganisms to the proposed liposomal interaction, unlike the chemotherapeutic compositions used to date; its total safety, as it lacks toxic or radioactive elements; its high selectivity with the use of specific anchoring elements, especially the use of monoclonal antibodies in cancer treatment; and its high lethal power when liposomal vesicles attach to the membranes of pathogenic microorganisms or the membranes of target cells.
[0039]
[0035] The specific anchoring elements—monoclonal antibodies, glycoproteins, or alcohols inserted into the liposome membrane, which are responsible for directing them toward the membranes of microorganisms or target cells—must be chosen to be selective enough to cause minimal side effects.
Claims
The Claims [1] CLAIMS 1. A composition for administration to a mammal or a human comprising at least one empty liposome in which at least one structural protein element is anchored to the liposome defining an opening of considerable size in the liposome membrane and specific anchoring elements, characterized in that the composition results in an effector capable of interacting with the membrane of a target cell or microorganism by substantially maintaining the opening in order to disrupt the osmotic balance and the opening being a mouth for the release of intracellular contents into the extracellular medium.
2. A composition to be administered to a mammal or a human being, according to claim 1, characterized in that the liposome is unilamellar and of specific lipid composition adapted to the cell or microorganism to be combated.
3. A composition to be administered to a mammal or a human being, according to claim 1, characterized in that the structural protein element is talin.
4. A composition to be administered to a mammal or a human being, according to claims 1 to 3, characterized by its use in the preparation of a treatment to combat altered cells and pathogenic microorganisms.
5. A composition to be administered to a mammal or a human being, according to claims 1 to 4, characterized by its use in the preparation of the treatment of a cancerous disease.
6. A composition to be administered to a mammal or a human being, according to claims 1 to 4, characterized by its use in the treatment of a viral disease.
